Iloperidone-induced galactorrhea in a middle-aged female

Indian Journal of Psychological Medicine

Volumn 34, Issue 4, 2012, Pages 396-398

  Dutta, Arghya ^a   Barua, Supartha ^a   Dan, Amitava ^a   Chakraborty, Kaustav ^b   Mandal, Manas ^a  

^a NRS MEDICAL COLLEGE   (India)

^b Department of Community Medicine   (India)

Author keywords

Antipsychotic; Galactorrhea; Iloperidone; Side effect

Indexed keywords

EID: 84875966348     PISSN: 02537176     EISSN: 09751564     Source Type: Journal    
DOI: 10.4103/0253-7176.108233     Document Type: Article

References (15)

1. Kapur S, Remington G. Atypical antipsychotics: New directions and newchallenges in the treatment of schizophrenia. Annu Rev Med 2001;52: 503-17.
2. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychoticsin the treatment of schizophrenia: Systematic overview and meta-regressionanalysis. BMJ 2000;321: 1371-6.
3. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000;22: 195-214.
4. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone and haloperidol on plasma prolactin levels in patients with schizophrenia.Clin Ther 2000;22: 1085-96.
5. Grunder G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K, et al. Neuroendocrine response to antipsychotics: effects of drug typeand gender. Biol Psychiatry 1999;45: 89-97.
6. Potkin SG. New advances in the treatment of schizophrenia. Introduction. J Clin Psychopharmacol 2008;28:S1-3.
7. Citrome L. Iloperidone for schizophrenia: A review of the efficacyand safety profile for this newly commercialised second-generationantipsychotic. Int J Clin Prac t2009;63: 1237-48.
8. Fanapt (iloperidone), prescribing information. Rockville, MD:Vanda Pharmaceuticals, Inc.; 2010.
9. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21 (2 Suppl): 106S-15S.
10. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, et al. Iloperidone binding to humanand rat dopamine and 5-HT receptors. Eur J Pharmacol 1996;317: 417-23.
11. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand bindingprofile of iloperidone: A broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychoticdisorders. Neuropsychopharmacology 2001;25: 904-14.
12. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safetyprofile of iloperidone: A pooled analysis of 6-week acute-phase pivotaltrials. J Clin Psychopharmacol 2008;28 :S12-9.
13. Stahl SM, Baroldi P, Feeney J, Wolfgang CD. The metabolic profile of iloperidone: Summary of phase II and III schizophrenia trials. Washington, DC: Presented at the 161st Annual Meeting of the American Psychiatric Association;2008.
14. Schotte A, Janssen PF, Gommeren W, Luyten WH, VanGompel P, Lesage AS, et al. Risperidone compared with new and referenceantipsychotic drugs: In vitro and in vivo receptor binding.Psychopharmacology (Berl) 1996;124: 57-73.
15. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats.J Pharmacol Exp Ther 2002;302: 1129-34.